Search

Your search keyword '"Neighbour, Helen"' showing total 37 results
Start Over Author "Neighbour, Helen"
37 results on '"Neighbour, Helen"'

1. Canadian multidisciplinary expert consensus on the use of biologics in upper airways: a Delphi study

Author

Thamboo, Andrew V., Lee, Melissa, Bhutani, Mohit, Chan, Charles, Chan, Yvonne, Chapman, Ken R., Chin, Christopher J., Connors, Lori, Dorscheid, Del, Ellis, Anne K., Gall, Richard M., Godbout, Krystelle, Janjua, Arif, Javer, Amin, Kilty, Shaun, Kim, Harold, Kirkpatrick, Gordon, Lee, John M., Leigh, Richard, Lemiere, Catherine, Monteiro, Eric, Neighbour, Helen, Keith, Paul K., Philteos, George, Quirt, Jaclyn, Rotenberg, Brian, Ruiz, Juan C., Scott, John R., Sommer, Doron D., Sowerby, Leigh, Tewfik, Marc, Waserman, Susan, Witterick, Ian, Wright, Erin D., Yamashita, Cory, and Desrosiers, Martin

Published
2023
Full Text
View/download PDF

2. Nasal and whole blood challenge models for allergic rhinitis and COPD

Author

Neighbour, Helen

Subjects
616.2
Abstract

Nasal allergen challenge (NAC) is a non-invasive model to study the mechanism of allergic rhinitis and effects of novel anti-inflammatory therapies. The repeatability and dose response of a single NAC was studied, followed by development of a daily repeat NAC model involving 4 challenges on consecutive days. However, the results of earlier published work could not be reproduced, since in nasal filter paper (FILT P) eluate in both studies there were no significant changes in levels of interleukin (IL)-4, IL-5 and IL-13. However the daily repeat NAC model did cause priming in terms of symptoms, eosinophils, and nasal lavage IL-5 and IL-13. Proposals were made for implementation of a synthetic absorptive matrix (SAM) as an alternative to Whatman's FILT P and also to deliver higher doses of allergen to the nose. Using SAM resulted in high serial levels of IL-4, IL-5 and IL-13 being detected in SAM eluates during the late phase after NAC (appendix). In cigarette smokers I requested subjects to exhale cigarette smoke through their noses, to provide a nasal cigarette smoke challenge method. FILT P is likely to distort detected levels of mediators in nasal secretions, but in FILT P eluates there were statistically significant elevations of IL-8 (p=0.01) and IL- 12p70 (p=0.02) at baseline in Chronic Obstructive Pulmonary Diseae (COPD) patients. However there were increases in nasal lavage MCP-1 at 8h in COPD patients and healthy controls following cigarette smoke (p=0.02). A cigarette smoke conditioned medium (CSCM) was employed to stimulate whole blood upregulation of CD11 b measured by flow cytometry on leukocytes. CSCM caused upregulation of neutrophil CD11 b, but this could not be inhibited by anti-oxidants. In contrast, menadione (MQ) stimulates intracellular generation of oxidants, and this caused neutrophil CD11 b upregulation that was inhibited by glutathione. Xanthine with xanthine oxidase (X+XO) generates an extracellular source of oxidants, and this caused an increase in neutrophil CD11 b on washed blood cells, that could also be inhibited by glutathione. NAC or cigarette smoke nasal challenge, as well as stimulation of human whole blood with oxidants, have potential as challenge models - but SAM should be used instead of FILT P.

Published
2009

8. Accumulation of Allergen-specific CD4+ T cells in the Airways after Segmental Allergen Challenge is Associated with Reduced Expression of T2 Chemoattractant Receptors on Allergen-specific CD4+ T cells in Blood

Author

Larché, Mark, primary, Tonti, Elena, additional, Mu, Jingyu, additional, Duong, MyLinh, additional, Ho, Terence, additional, Killian, Kieran, additional, Neighbour, Helen, additional, French, Deanna, additional, Murphy, Desmond, additional, El-Gammal, Amani, additional, Howie, Karen, additional, Wiltshire, Lesley, additional, Mitchell, Patrick, additional, Munoz, Caroline, additional, Obminski, Caitlin, additional, Kipling, Cheryl, additional, Gergen, Peter, additional, O'Byrne, Paul, additional, Kwok, William, additional, and Gauvreau, Gail, additional

Published
2021
Full Text
View/download PDF

15. Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre‐ and post‐peptide immunotherapy: An open‐label clinical study.

Author

Kim, Young Woong, Tonti, Elena, Hickey, Pascal, Ellis, Anne K., Neighbour, Helen, Larché, Mark, and Tebbutt, Scott J.

Subjects
SNEEZING, ALLERGIC rhinitis, ANDROGEN receptors, NEURAL cell adhesion molecule, ALLERGENS, BLOOD cell count, IMMUNOTHERAPY
Abstract

Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre- and post-peptide immunotherapy: An open-label clinical study I To the Editor i , We investigated immunological changes in peripheral blood samples obtained from individuals with allergic rhinitis (AR), triggered by exposure to cat allergen, who were receiving peptide immunotherapy. The association of allergic rhinitis severity with neutrophil-lymphocyte and platelet-lymphocyte ratio in adults. [Extracted from the article]

Published
2021
Full Text
View/download PDF

18. Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge

Author

Kim, Young Woong, primary, Singh, Amrit, additional, Shannon, Casey P., additional, Thiele, Jenny, additional, Steacy, Lisa M., additional, Ellis, Anne K., additional, Neighbour, Helen, additional, Gliddon, Daniel R., additional, Hickey, Pascal L. C., additional, Larché, Mark, additional, and Tebbutt, Scott J., additional

Published
2017
Full Text
View/download PDF

21. The Allergic Rhinitis – Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies

Author

Ellis, Anne K, primary, Soliman, Mena, additional, Steacy, Lisa, additional, Boulay, Marie-Ève, additional, Boulet, Louis-Philippe, additional, Keith, Paul K, additional, Vliagoftis, Harissios, additional, Waserman, Susan, additional, and Neighbour, Helen, additional

Published
2015
Full Text
View/download PDF

32. AllerGen’s 8th research conference

Author

Arrieta, Marie-Claire, Arevalos, Andrea, Stiemsma, Leah, Chico, Marta E., Sandoval, Carlos, Jin, Minglian, Walter, Jens, Cooper, Phil, Finlay, Brett, Bernatchez, Emilie, Gold, Matthew J., Langlois, Anick, Blais-Lecours, Pascale, Duchaine, Caroline, Marsolais, David, McNagny, Kelly M., Blanchet, Marie-Renée, Brubacher, Jordan, Chhetri, Bimal, Sabaliauskas, Kelly, Bassil, Kate, Kwong, Jeff, Coates, Frances, Takaro, Tim K., Chow, Angela, Miller, Gregory E., Chen, Edith, Mandhane, Piushkumar J., Turvey, Stuart E., Elliott, Susan J., Becker, Allan B., Subbarao, Padmaja, Sears, Malcolm R., Kozyrskyj, Anita L., Dubeau, Aimée, Lu, Zihang, Balkovec, Susan, Kowalik, Krzysztof, Gustafsson, Per, Ratjen, Felix, Edgar, Rachel D., Bush, Nicole R., MacIssac, Julie L., McEwen, Lisa M., Boyce, Thomas W., Kobor, Michael S., Emmerson, Melanie, Shen, Bingqing, Moraes, Theo J., Gabrielli, Sofianne, Clarke, Ann, Eisman, Harley, Morris, Judy, Joseph, Lawrence, LaVieille, Sebastien, Ben-Shoshan, Moshe, Islam, Sumaiya A., Brückmann, Christof, Nieratschker, Vanessa, Jamieson, Kyla C., Proud, David, Kanagaratham, Cynthia, Camateros, Pierre, Kopriva, Frantisek, Henri, Jennifer, Hajduch, Marian, Radzioch, Danuta, Kang, Liane J., Koleva, Petya T., Field, Catherine J., Konya, Tedd, Scott, James A., Konya, Theodore, Azad, Meghan B., Brook, Jeff, Guttman, David, Kumari, Manjeet, Bridgman, Sarah L., Tun, Mon H., Mandal, Rupasri, Wishart, David S., Lee, Amy H. Y., Xia, Jeff, Gill, Erin, Hancock, Bob, Maestre, Danay, Sutherland, Darren, Hirota, Jeremy, Pena, Olga, Carlsten, Christopher, Jones, Meaghan J., MacIsaac, Julia L., Dow, William H., Rosero-Bixby, Luis, Rehkopf, David H., Morimoto, Takeshi, Smith, Steven G., Oliveria, John-Paul, Beaudin, Suzanne, Schlatman, Abbey, Howie, Karen, Obminski, Caitlin, Nusca, Graeme, Sehmi, Roma, Gauvreau, Gail M., O’Byrne, Paul M., North, Michelle, Peng, Cheng, Sanchez-Guerra, Marco, Byun, Hyang-Min, Ellis, Anne K., Baccarelli, Andrea A., Okeme, Joseph O., Dhal, Suman, Saini, Aman, Diamond, Miriam L., Olesovsky, Christopher J., Salter, Brittany M., Wang, Michael, Lacy, Paige, O’Sullivan, Michael J., Park, Chan Y., Fredberg, Jeffrey J., Lauzon, Anne-Marie, Martin, James G., Ryu, Min Hyung, Mookherjee, Neeloffer, Simons, Elinor, Lefebvre, Diana, Dai, David, Singh, Amrit, Shannon, Casey P., Kim, Young Woong, Yang, Chen Xi, Mark FitzGerald, J., Boulet, Louis-Philippe, Tebbutt, Scott J., Singhera, Gurpreet K., JasemineYang, S., Dorscheid, Delbert R., Sinnock, Hasantha, Goruk, Susan, Tavakoli, Hamid, Lynd, Larry D., Sadatsafavi, Mohsen, Tenn, Mark W., Thiele, Jenny, Adams, Daniel E., Steacy, Lisa M., Torabi, Bahar, De Schryver, Sarah, Lejtenyi, Duncan, Baerg, Ingrid, Chan, Edmond S., Mazer, Bruce D., Tran, Maxwell M., Dai, Wei Hao, Lou, Wendy, Chari, Radha S., Conway, Edward M., Neighbour, Helen, Larché, Mark, and Tebbutt, Scott J

Published
2016
Full Text
View/download PDF

35. Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge.

Author

Young Woong Kim, Singh, Amrit, Shannon, Casey P., Thiele, Jenny, Steacy, Lisa M., Ellis, Anne K., Neighbour, Helen, Gliddon, Daniel R., Hickey, Pascal L. C., Larché, Mark, and Tebbutt, Scott J.

Subjects
*ALLERGIC rhinitis, *ALLERGENS, *FUZZY algorithms, *NASAL mucosa, *NEUTROPHILS
Abstract

Nasal allergen challenge (NAC) is a human model of allergic rhinitis (AR) that delivers standardized allergens locally to the nasal mucosa allowing clinical symptoms and biospecimens such as peripheral blood to be collected. Although many studies have focused on local inflammatory sites, peripheral blood, an important mediator and a component of the systemic immune response, has not been well studied in the setting of AR. We sought to investigate immune gene signatures in peripheral blood collected after NAC under the setting of AR. Clinical symptoms and peripheral blood samples from AR subjects were collected during NAC. Fuzzy c-means clustering method was used to identify immune gene expression patterns in blood over time points (before NAC and 1, 2, and 6 h after NAC).We identified and validated seven clusters of differentially expressed immune genes after NAC onset. Clusters 2, 3, and 4 were associated with neutrophil and lymphocyte frequencies and neutrophil/lymphocyte ratio after the allergen challenge. The patterns of the clusters and immune cell frequencies were associated with the clinical symptoms of the AR subjects and were significantly different from healthy nonallergic subjects who had also undergone NAC. Our approach identified dynamic signatures of immune gene expression in blood as a systemic immune response associated with clinical symptoms after NAC. The immune gene signatures may allow cross-sectional investigation of the pathophysiology of AR and may also be useful as a potential objective measurement for diagnosis and treatment of AR combined with the NAC model. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

36. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

Author

Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, and Hansel TT

Subjects
Adult, Aged, Antibodies, Monoclonal pharmacology, Asthma immunology, Cytokines analysis, Double-Blind Method, Eosinophils immunology, Female, Humans, Immunologic Factors pharmacology, Infliximab, Male, Peak Expiratory Flow Rate drug effects, Respiratory Function Tests, Sputum chemistry, Tumor Necrosis Factor-alpha immunology, Antibodies, Monoclonal therapeutic use, Asthma drug therapy, Immunologic Factors therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Rationale: Neutralization of tumor necrosis factor-alpha (TNF-alpha) is an effective antiinflammatory therapy for several chronic inflammatory diseases., Methods and Objectives: We undertook a double-blind, placebo-controlled, parallel-group design study in 38 patients with moderate asthma treated with inhaled corticosteroids but symptomatic during a run-in phase. Infliximab (5 mg/kg) or placebo was administered by intravenous infusion at Weeks 0, 2, and 6. We assessed clinical response by monitoring lung function, symptoms, and inhaled beta(2)-agonist usage using hand-held electronic devices., Results: The primary endpoint, change in morning PEF at Days 50-56 compared with the last 7 d of the run-in, was not significantly different on treatment. However, infliximab was associated with a decrease in mean diurnal variation of PEF at Week 8 (p = 0.02; 95% confidence interval [CI], -8.1 to -0.72). Furthermore, there was a decrease in the number of patients with exacerbations of asthma (p = 0.01; 95% CI, 4.4 to 52.7) and an increased probability of freedom from exacerbation with time (p = 0.03) in patients on infliximab (n = 14) compared with placebo (n = 18). In addition, infliximab decreased levels of TNF-alpha (p = 0.01) and other cytokines in sputum supernatants. There were no serious adverse events related to the study agent., Conclusions: Treatment with infliximab was well tolerated and caused a decrease in the number of patients with exacerbations in symptomatic moderate asthma. The promising preliminary findings underscore the need to evaluate therapy directed against TNF-alpha in larger trials enrolling patients with more severe asthma.

Published
2006
Full Text
View/download PDF

37. Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease.

Author

Hansel TT, Tennant RC, Tan AJ, Higgins LA, Neighbour H, Erin EM, and Barnes PJ

Subjects
Asthma physiopathology, Clinical Trials as Topic, Humans, Pulmonary Disease, Chronic Obstructive physiopathology, Theophylline adverse effects, Asthma drug therapy, Pulmonary Disease, Chronic Obstructive drug therapy, Theophylline pharmacology, Theophylline therapeutic use
Abstract

Despite having been recognized for a long time as a cheap and effective therapy for the treatment of asthma and chronic obstructive pulmonary disease (COPD), theophylline is relegated to third-line therapy in the treatment of airway diseases due to the drug's frequent side effects and relatively low efficacy. However, regardless of the current situation, there are reasons for thinking that the use of theophylline, in addition to inhaled steroids, may come back into fashion for the treatment of chronic asthma, as it may have an anti-inflammatory and immunomodulatory effect when given in low doses. At these low doses, the drug is easier to use, side effects are uncommon and the problems of drug interaction are less of an issue, thus making the clinical use of theophylline less complicated. In COPD, low-dose theophylline is the first drug to demonstrate clear anti-inflammatory effects, and thus it may even have a role in preventing progression of the disease. Furthermore, the reversal of the steroid resistance induced by oxidative stress suggests that theophylline may increase responsiveness to corticosteroids.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results